ReviewInternational journal of general medicine2025
Endometrial Changes Associated with Mifepristone: A Review.
Review in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The role of mifepristone in managing myoma: a systematic review and meta-analysis of uterine parameters.BMC women's health · 2026Pooled it
- Epicatechin Gallate Blocks GC/GR Signaling to Suppress Stress-Induced Myeloid Differentiation of HSPCs and Subsequent TNBC Metastasis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Progesterone receptor antagonism by mifepristone impairs trophoblast stemness and promotes apoptosis through upregulation of PDCD4.Cell & bioscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mifepristone is a well-established pharmaceutical agent in obstetrics and gynecology, which has expanded its therapeutic applications to Cushing's syndrome, meningioma, and even mental disease. The incidence of progesterone receptor modulator-associated endometrial changes (PAECs), characterized by cystic glandular dilatation and architectural complexity that mimic endometrial hyperplasia or carcinoma, is increasing. The precise molecular mechanisms remain incompletely understood. Hormonal influences may be central to PAECs pathogenesis. Histological heterogeneity has been observed between ectopic versus eutopic endometrium. The use of mifepristone at low doses (≤10 mg/d) in young women during the early follicular phase appears to be safe. Monitoring of estradiol(E
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.